FibroBiologics, Inc.
FBLG
$0.26
-$0.02-5.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.79M | 2.25M | 2.45M | 2.75M | 2.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.59M | 5.04M | 4.49M | 4.53M | 3.71M |
| Operating Income | -2.59M | -5.04M | -4.49M | -4.53M | -3.71M |
| Income Before Tax | -3.24M | -5.78M | -4.66M | -4.97M | -3.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.24M | -5.78M | -4.66M | -4.97M | -3.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.24M | -5.78M | -4.66M | -4.97M | -3.10M |
| EBIT | -2.59M | -5.04M | -4.49M | -4.53M | -3.71M |
| EBITDA | -2.52M | -4.97M | -4.43M | -4.48M | -3.67M |
| EPS Basic | -0.05 | -0.13 | -0.12 | -0.14 | -0.09 |
| Normalized Basic EPS | -0.03 | -0.08 | -0.08 | -0.08 | -0.06 |
| EPS Diluted | -0.05 | -0.13 | -0.12 | -0.14 | -0.09 |
| Normalized Diluted EPS | -0.03 | -0.08 | -0.08 | -0.08 | -0.06 |
| Average Basic Shares Outstanding | 60.18M | 43.07M | 38.64M | 36.67M | 34.13M |
| Average Diluted Shares Outstanding | 60.18M | 43.07M | 38.64M | 36.67M | 34.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |